Welcome to our dedicated page for Briacell Therapeutics SEC filings (Ticker: BCTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching through Briacell Therapeutics Corp’s dense clinical disclosures can feel like decoding lab notes. Trial data, cash runway estimates, and equity grants are scattered across 10-K footnotes, 10-Q updates, and rapid-fire 8-Ks on study results. Stock Titan’s AI-powered engine turns those technical pages into clear, cancer-focused insights, so you can spot pivotal milestones in minutes instead of hours.
Need the “Briacell insider trading Form 4 transactions” before the next data read-out? Our platform streams real-time Form 4 insider transactions and flags buying or selling by scientists and directors. Wondering how the latest dilution affects runway? The “Briacell quarterly earnings report 10-Q filing” is parsed line-by-line, with AI notes that highlight trial spending, NIH grant income, and going-concern language. For deeper due diligence, open the “Briacell annual report 10-K simplified” module: it links R&D milestones to risk factors and summarizes every clinical cohort, making “understanding Briacell SEC documents with AI” straightforward.
All filings—10-K, 10-Q, 8-K material events explained, S-3 capital raises, and the “Briacell proxy statement executive compensation”—are indexed the moment EDGAR publishes them. Investors use these AI summaries to: track “Briacell executive stock transactions Form 4”, compare quarter-over-quarter burn rates, and gauge how new trial arms impact valuation. Whether you’re researching “Briacell earnings report filing analysis” or prepping questions for management, our comprehensive coverage keeps the immuno-oncology picture crystal clear.
BriaCell Therapeutics (BCTX) filed its 10-K, highlighting steady clinical progress and a leaner cost base. The company’s lead immunotherapy, Bria-IMT, is in a pivotal Phase 3 study in metastatic breast cancer with the checkpoint inhibitor retifanlimab and holds FDA Fast Track Designation. The Data Safety Monitoring Board raised no safety concerns in reviews on December 2, 2024, March 20, 2025, and June 24, 2025. As of April 22, 2025, the study had consented over 100 and enrolled over 75 patients, with top-line data anticipated as early as H1‑2026.
Bria-OTS, the personalized off‑the‑shelf program, showed a complete resolution of a lung metastasis in the first treated patient and has advanced to combination dosing following safety clearance. R&D expenses were $21,150,628 for the year ended July 31, 2025 (vs. $26,442,821 in 2024). The aggregate market value of non‑affiliate equity was $94,477,705 based on a $50.20 share price as of January 31, 2025. 1,883,906 common shares were outstanding as of October 15, 2025. The filing also notes substantial doubt about the company’s ability to continue as a going concern.
Schedule 13G filed by Jeremy Myung Jae Plambeck reports his beneficial ownership in BriaCell Therapeutics Corp. The filing lists 4,329.72 directly held common shares, 29,956 BCTXW warrants (reported as 2,995.6 common-share equivalents at a 10:1 exercise ratio) and 63,132.88 BCTXZ rights (reported as 6,313.29 common-share equivalents at a 10:1 conversion ratio). The filing states an aggregate ownership equal to
FAQ
What is the current stock price of Briacell Therapeutics (BCTX)?
What is the market cap of Briacell Therapeutics (BCTX)?
